Today: 24 May 2026
Cemtrex (CETX) stock ends lower as FY2025 results tout operating profit but 10-K flags going-concern doubt
30 December 2025
2 mins read

Cemtrex (CETX) stock ends lower as FY2025 results tout operating profit but 10-K flags going-concern doubt

NEW YORK, December 29, 2025, 23:19 ET — Market closed

  • Cemtrex shares ended Monday down 7.5% at $2.11.
  • The company reported fiscal 2025 revenue growth and a return to operating income in an after-market release.
  • An annual filing showed a wider net loss and disclosed “going concern” uncertainty tied to near-term funding and debt.

Cemtrex, Inc. shares closed down 7.46% at $2.11 on Monday, before the company released its full-year results after the bell showing a return to operating profit.

The timing matters because the filing and earnings release are the first full look at Cemtrex’s capital structure after a volatile year for thinly traded microcaps. Investors are weighing whether the company’s operating turnaround can translate into sustained cash generation without further dilution.

That scrutiny sharpened after Cemtrex’s annual report flagged “substantial doubt” about its ability to continue as a going concern — an accounting warning that the company may need additional funding to operate over the next 12 months. Cemtrex, Inc.

In its earnings release, the security- and industrial-services company said fiscal 2025 revenue rose to $76.5 million from $66.9 million a year earlier, while operating income was $0.5 million versus an operating loss of $5.3 million. The security segment posted 20% revenue growth to $38.4 million, and industrial services revenue rose 9% to $38.0 million, the company said.

“Fiscal 2025 marked a major operating inflection for Cemtrex,” CEO and Chairman Saagar Govil said in the release. He added that some capital-markets-related costs were not expected to recur. GlobeNewswire

The operating result did not carry through to the bottom line. Cemtrex reported a fiscal 2025 net loss of $28.3 million, its annual report showed.

A large part of that loss came from warrant-related charges, including a $15.1 million loss on the exercise of warrant liabilities and a $10.9 million loss from changes in the fair value of warrant liabilities, the filing showed. Warrants are contracts that give holders the right to buy shares later; when they’re booked as liabilities, their value can swing with the stock price and flow through earnings.

The 10-K also showed cash, cash equivalents and restricted cash of $6.35 million at Sept. 30, and total debt of $13.5 million at year-end.

Cemtrex said it had incurred substantial losses and faced more than $12.1 million of debt obligations over the next fiscal year, factors it said raised substantial doubt about its ability to continue as a going concern. The company said it has historically satisfied some short-term liabilities by issuing common stock.

The annual report also disclosed that Cemtrex invested about $1.0 million in Solana tokens during fiscal 2025 and staked the holdings, with fair-value changes recorded in net income.

Cemtrex traded between $2.095 and $2.23 during Monday’s session, while the Nasdaq index slipped about 0.5%, according to Investing.com data.

Before Tuesday’s session, investors are likely to focus on the company’s “liquidity and flexibility” message versus the going-concern language in the filing, and whether Cemtrex returns to the equity market to refinance or extend maturities. GlobeNewswire+1

Management also said it has two acquisitions in process and expects to close them in the near term, putting any deal updates — and their financing — on the short list of catalysts.

For traders, Monday’s low around $2.10 is a key near-term level, with the session high near $2.23 acting as the first resistance point if volume returns after the results.

Stock Market Today

  • Cigna Group (CI) Stock Valuation Shows 15.7% Undervaluation After Recent Gains
    May 23, 2026, 7:46 PM EDT. Cigna Group (CI) shares closed at $286.24, reflecting a recent 1.5% daily gain and 4.2% monthly increase, despite a 7.5% decline over the past year. Long-term returns remain solid with 24.01% and 21.02% gains over three and five years respectively. Analysts estimate a fair value of $339.58, suggesting the stock is about 15.7% undervalued amid rising demand in specialty pharmacy, a sector exceeding $400 billion. Growth drivers include double-digit revenue increases in CuraScript and Accredo. However, investors should consider risks like heightened scrutiny of pharmacy benefit management and potential passing of rising medical and drug costs to clients. Reviewing key reward and risk factors is advised before investment decisions.

Latest articles

Exxon Mobil Corporation Wants a Texas Legal Home as Shareholder Battles Mount

Exxon Stock Moves in Holiday Week Trading

24 May 2026
Exxon Mobil shares closed at $154.92 Friday, down 0.24% on the day and 1.9% for the week, ahead of the Memorial Day market closure. The stock retreated from a midweek high as investors weighed possible Venezuela oil deals and volatile crude prices. Exxon’s annual meeting is set for Wednesday, with a shareholder vote on moving its legal home to Texas. Brent crude settled at $103.54 a barrel, posting a weekly loss.
Why SoFi Technologies Stock Is Slipping After Its PrimaryBid Deal

SoFi Moves Back Into Focus After Unnoticed Deal

24 May 2026
SoFi closed Friday at $15.62, down 3 cents for the day and nearly flat for the week. Trade publications reported SoFi acquired Peach Finance, a California lending software startup; terms were not disclosed. U.S. stock trading will resume Tuesday after Memorial Day.
Synopsys stock closes higher as traders eye Dec. 30 lawsuit deadline and Fed minutes
Previous Story

Synopsys stock closes higher as traders eye Dec. 30 lawsuit deadline and Fed minutes

Coca-Cola Consolidated (COKE) stock slides nearly 4% into year-end — what traders watch next
Next Story

Coca-Cola Consolidated (COKE) stock slides nearly 4% into year-end — what traders watch next

Go toTop